Vistin Pharma plans to raise up to Nkr300m ($38.82m) in gross proceeds through a private placement of shares of its common stock.

The company will divest 26,785,715 shares to Norwegian and international investors and has received significant pre-commitments.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The proceeds are intended to be used for setting up energy trading business and trading activities.

Vistin Pharma is a Norway-based active pharmaceutical ingredients (API) provider.

“China Traditional Chinese Medicine Holdings plans to raise approximately HK$2.67bn ($341.3m).”

Shenzhen Neptunus Bioengineering is planning to make a public offering of short-term financing bonds to raise CNY2bn ($315.58m) in gross proceeds.

The proceeds are intended to be used to repay loans from financial institutions and to supplement working capital.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Shenzhen Neptunus manufactures and distributes pharmaceutical products.

China Traditional Chinese Medicine Holdings plans to raise approximately HK$2.67bn ($341.3m) in gross proceeds through the private placement of shares.

The company will place 604.3 million shares priced at HK$4.43 ($0.56) a share, as part of the transaction.

Ping An Life Insurance Company of China has subscribed to the placement.

The proceeds are intended to be used to expand the company’s traditional Chinese medicine business, as well as to make acquisitions, repay debts, supplement working capital, and for research and development (R&D).

China Traditional Chinese Medicine Holdings is based in Hong Kong.